CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
嵌合抗原受体（CAR）T 细胞治疗：一种新的基因工程肿瘤免疫治疗方法
英文原题：Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.
查看英文原题
Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞治疗实体瘤面临重大挑战。由于缺乏内皮白细胞黏附分子，CAR-T 细胞无法有效通过肿瘤血管屏障。实体瘤环境中的其他免疫抑制机制也可能阻碍CAR-T 细胞浸润、发挥活性并维持持久性。从血液内部靶向癌症血管内皮的代谢靶点，或许能简化CAR-T 抗癌过程。本文依据上述原理探讨CAR-T 治疗肿瘤细胞，并特别关注肿瘤静脉递送。CAR-T 细胞也可通过设计，使其能够被便捷、安全且有效地转移。
展开英文摘要原文
Chimeric antigen receptor (CAR T) cell treatment for solid tumours faces significant challenges. CAR T cells are unable to pass the vascular barrier in tumours due to a lack of endothelial leukocyte adhesion molecules. The invasion, activity, and durability of CAR T cells may be hampered by additional immunosuppressive mechanisms present in the solid tumour environment.
The use of CAR T cells to attack cancer vascular endothelial metabolic targets from within the blood may simplify the fight against cancer. These are the principles that govern our examination of CAR T cell treatment for tumor cells, with a specific eye toward tumour venous delivery. CAR T cells may also be designed such that they can be readily, safely, and successfully transferred.
论文信息
- 作者
- Singh AK、Malviya R、Singh A、Sundram S、Mishra S
- 第一作者单位
- Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.India
- 通讯作者单位
- Department of Pharmaceutical Sciences and Technology, Madan Mohan Malaviya University of Technology, Gorakhpur, Uttar Pradesh, India.India
- 期刊
- Current cancer drug targets2023
- 原文标识
- PubMed 36173082 · DOI 10.2174/1568009622666220928141727